Abstract: A cancer therapeutic agent according to an embodiment of the present invention contains, as active ingredients, IL-18 and one or more antibodies selected from the group consisting of an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-PD-L2 antibody, an anti-CTLA-4 antibody, an anti-CD25 antibody, an anti-CD33 antibody, and an anti-CD52 antibody.

Abstract: A cancer therapeutic agent according to an embodiment of the present invention contains, as active ingredients, IL-18 and one or more antibodies selected from the group consisting of an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-PD-L2 antibody, an anti-CTLA-4 antibody, an anti-CD25 antibody, an anti-CD33 antibody, and an anti-CD52 antibody.

Abstract: A protein which induces the IFN-? production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.

Abstract: A protein which induces the IFN-? production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.

Abstract: A V?9V?2 T cell proliferation agent includes at least a bisphosphonate, interleukin 2, and interleukin 18. Since IL-18 has properties that improve cell viability by inhibiting cell death, IL-18 is presumably capable of acting as a cofactor for the bisphosphonate so as to significantly increase the effect of V?9V?2 T cell proliferation by the bisphosphonate and the IL-2. This allows providing a V?9V?2 T cell proliferation agent capable of growing V?9V?2 T cells with a proliferated efficiency significantly high compared to conventional methods so that the proliferated V?9V?2 T cells have a high antitumor activity and high cytokine productivity.

Abstract: Provided is a method for preventing or treating cisplatin induced nephrotoxicity, which comprises administering a patient who is receiving cisplatin a therapeutically effective amount of an aldosterone blocker such as eplerenone or spironolactone.

Abstract: A V?9V?2 T cell proliferation agent includes at least a bisphosphonate, interleukin 2, and interleukin 18. Since has properties that improve cell viability by inhibiting cell death, IL-18 is presumably capable of acting as a cofactor for the bisphosphonate so as to significantly increase the effect of V?9V?2 T cell proliferation by the bisphosphonate and the IL-2. This allows providing a V?9V?2 T cell proliferation agent capable of growing V?9V?2 T cells with a proliferated efficiency significantly high compared to conventional methods so that the proliferated V?9V?2 T cells have a high antitumor activity and high cytokine productivity.

Abstract: A human IFN-? inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel INF-? inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating diseases susceptive to treatment with INF-?, and methods for enhancing the cytotoxicity of NK cells or for inducing the formation of LAK cells, such as to treat tumors and malignant pathologies.

Abstract: A human IFN-? inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel INF-? inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating diseases susceptive to treatment with INF-?, and methods for enhancing the cytotoxicity of NK cells or for inducing the formation of LAK cells, such as to treat tumors and malignant pathologies.

Abstract: A human IFN-? inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel IFN-? inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating diseases susceptive to treatment with IFN-?, and methods for enhancing the cytotoxicity of NK cells or for inducing the formation of LAK cells, such as to treat tumors and malignant pathologies.

Abstract: A protein which induces the IFN-&ggr; production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein. Fragments of the protein can be used for production of antibodies, and can be produced recombinantly using appropriate medric acids, host cells and vectors. Fragments of nuclear acids may also be used as probes.

Abstract: A protein which induces the IFN-&ggr; production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.

Abstract: A polypeptide which has a molecular weight of 18,500±3,000 daltons on SDS-PAGE and a pI of 4.9±1.0 on chromatofocusing. The polypeptide strongly induces the IFN-&ggr; production by immunocompetent cells with only a small amount, and does not cause serious side effects even when administered to human in a relatively-high dose. It can be used to treat and/or prevent malignant tumors, viral diseases, bacterial infectious diseases, and immune diseases.

Abstract: DNA encoding a murine protein capable of inducing the production of interferon-.gamma. by immunocompetent cells is described. The native protein from mouse liver has a molecular weight of 19.+-.5 kDa, a pI of 4.8.+-.1.0, and the amino acid sequence shown in SEQ ID NO: 2. Methods for producing the protein in recombinant expression systems including E. coli are provided.

Abstract: A protein which induces IFN-.gamma. production by immunocompetent cells and has a molecular weight of 19,000.+-.5,000 daltons on SDS-PAGE or gel filtration and a pI of 4.8.+-.1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.

Abstract: A process for producing a carboxylic acid ester which comprises reacting a carboxylic acid with an alcohol in the presence of an acid catalyst to produce a reaction solution and neutralizing the reaction solution, characterized by using a countercurrently contacting column for neutralization, into which the esterified reaction solution is introduced at the lower portion of the column, an aqueous strong alkaline solution at a middle portion and an aqueous weak alkaline solution at an upper portion, removing a neutralized oil phase containing the carboxylic acid ester from the top of the column and removing an aqueous phase from the bottom, thereby continuously neutralizing the reaction solution.

Abstract: A stabilized resin composition comprising a resin, a piperidine derivative represented by the formula (III) ##STR1## wherein R.sub.1 is a hydrogen atom or an alkyl group having 1 to 3 carbom atoms; R.sub.2 is a hydrogen atom or an alkyl group having from 1 to 2 carbon atoms; and R.sub.3 and R.sub.4 are each independently an alkyl group having 1 to 12 carbon atoms, a phenol-type antioxidant and a sulfur-containing antioxidant. The composition simultaneously meets heat resistance, oxidation resistance and light resistance requirements.

Abstract: An ultraviolet ray absorbing agent comprising as an active ingredient a spiro compound having a spiro ring structure in the molecule, said spiro compound being represented by the general formula ##STR1## wherein, Y is ##STR2## A is ##STR3## R.sub.1 is hydrogen, halogen, lower alkyl of 1 to 4 carbon atoms, lower alkoxyl of 1 to 4 carbon atoms, carboxyl, or sulfo, R.sub.2 is hydrogen or alkyl of 1 to 12 carbon atoms, R.sub.3 and R.sub.4 are alkyls of 1 to 12 carbon atoms, X is methylene, oxygen, imino, sulfur, sulfinyl, or sulfonyl, and n is an integer of 1 to 12.

Abstract: 3,9-bis{2-[3-(3-tert-butyl-4-hydroxy-5-methylphenyl) propionyloxy]-1,1-dimethylethyl}-2,4,8,10-tetraoxaspiro[5.5] undecane having a novel crystalline structure which, when subjected to Cu-K.sub..alpha. X-ray diffraction, shows sharp X-ray diffraction peaks at angles of diffraction, 2.theta.=4.2.degree. and 2.theta.=10.6.degree.. Also provided is a method for producing this compound, using a certain recrystallization solvent.

Abstract: A process for producing a bisphenol compound useful as deterioration preventor capable of stabilizing organic substances against the decompositions caused by heat, light and oxygen, represented by the following general formula: ##STR1## wherein R.sub.1 represents alkyl group having 1 to 3 carbon atoms, alkenyl group having 2 to 4 carbon atoms, phenyl group or 2-phenylethenyl group; R.sub.2 represents alkyl group having 1 to 5 carbon atoms, or cyclohexyl group; R.sub.3 represents alkyl group having 1 to 9 carbon atoms, cyclohexyl group or phenyl group; and R.sub.4 represents alkyl group having 1 to 11 carbon atoms or phenyl group, which comprises reacting a carboxylic acid represented by the following general formula: ##STR2## wherein R.sub.1 is as defined above, with a bisphenol compound represented by the following general formula: ##STR3## wherein R.sub.2, R.sub.3 and R.sub.